

Confidential Disclosure Agreement will be required to receive copies of the patent applications.

#### **Standard Slide for Testing the Axial Resolution of Microscopes**

Edward Cho and Stephen Lockett (NCI/SAIC—Frederick)  
DHHS Reference No. E-148-2005/0—  
Research Tool  
*Licensing Contact:* Michael Shmilovich;  
301/435-5019;  
[shmilovm@mail.nih.gov](mailto:shmilovm@mail.nih.gov)

Available for licensing as a research tool for both internal use or commercial distribution is a test slide for three-dimensional resolution. The U.S. Government has not applied for patent rights on this invention. The resolution of an optical system must be accurately measured in multiple dimensions when acquiring imaging data for biological or materials applications. Such measurements permit quantitative analysis of data obtained from the optical system. The invention is a microscope slide that can be adapted for a variety of microscopy applications (e.g., electron, confocal, widefield fluorescence, and deconvolution) to measure and resolve multiple points or objects in three-dimensional space by having objects of known distances separated in three dimensions. The slide is ideally suited to test the precision of the resolution of an optical system to determine the quality of the optical system and its separate components. This allows for proper quality control of existing instruments, as well as a method to evaluate instruments that are being considered for purchase. The slide is designed with markings having known distances to determine resolution and allows for the quantification of spatial data.

#### **Use of Targeted Bone Marrow Cell Infiltration To Induce Pigmentation and Hair Growth in Skin**

Riccardo Cassiani-Ingoni (NINDS); U.S. Provisional Application filed 18 Mar 2005  
(DHHS Reference No. E-343-2004/0—US-01)

*Licensing Contact:* Fatima Sayyid; (301) 435-4521; [sayyidf@mail.nih.gov](mailto:sayyidf@mail.nih.gov)

A long standing problem in skin research has been the difficulty of inducing stem cells such as bone marrow cells, to infiltrate the skin. Such infiltration could be the basis of numerous therapeutic interventions. The present invention describes a method of using localized inflammation to induce targeted bone marrow cell effects in the skin. Among the conditions treated in the preliminary trials are hair and pigmentation loss.

Alopecia (hair loss) is a common condition that results from diverse causes such as altered physiology, surgical trauma and/or certain drugs. The present invention relates to methods of increasing hair growth and melanocyte proliferation. Such methods include administration of bone marrow cells, an agent that mobilizes bone marrow cells or a combination thereof.

#### **Creation and Characterization of Carcinogen-Altered Mouse Epidermal Cell Lines**

Stuart H. Yuspa (NCI)  
DHHS Reference No. E-154-2004/0—  
Research Tool  
*Licensing Contact:* Jesse S. Kindra; (301) 435-5559; [kindraj@mail.nih.gov](mailto:kindraj@mail.nih.gov)

The invention relates to the creation of three (3) cell lines that may be used as models of putative initiated cancer cells. The cell lines can be used in basic research assays and low/high throughput screening assays.

Cell line 308 evolved from a calcium-resistant focus from adult mouse epidermis that was exposed to the carcinogen, 7,12-dimethylbenz[a]anthracene (DMBA). Cell lines F and D were derived by treating primary newborn mouse epidermal cells in culture with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and DMBA, respectively. These three (3) nontumorigenic cell lines derived from differentiation-resistant, carcinogen-induced foci may be considered to be putative initiated cells.

The creation and characterization of the cell lines was published in Yuspa and Morgan, 1981, "Mouse Skin Cells Resistant to Terminal Differentiation Associated with Initiation of Carcinogenesis," *Nature*, vol. 72-74; and Hennings *et al.*, 1987, "Response of Carcinogen-Altered Mouse Epidermal Cells to Phorbol Ester Tumor Promoters and Calcium," *The Society for Investigative Dermatology, Inc.*, vol. 88, no. 1, 60-65.

#### **Conditionally Immortalized Cell Line of Metanephric Mesenchyme**

Zoia B. Levashova *et al.* (NCI)  
DHHS Reference No. E-181-2001/0—  
Research Tool  
*Licensing Contact:* Marlene Shinn-Astor; (301) 435-4426; [shinnm@mail.nih.gov](mailto:shinnm@mail.nih.gov)

An immortalized rat cell line with characteristics of undifferentiated kidney blastemal cells has been established (*Kidney Int.* 60:2075, 2003). Not only can these cells be maintained in culture, but they retain the capacity to differentiate into epithelial-like cells. This cell line may have utility in studying the molecular mechanisms of

mesenchymal-epithelial conversion, kidney development, and kidney tumorigenesis. It may also have future application in the development of renal xenographs or other forms of kidney tissue transplantation.

#### **A Transgenic Mouse Model for Tetracycline Regulation of Active TGFbeta1 in Mice: tetO TGFbeta1**

Adam B. Glick (NCI)  
DHHS Reference No. E-300-1999/0—  
Research Tool.  
*Licensing Contact:* Marlene Shinn-Astor; (301) 435-4426; [shinnm@mail.nih.gov](mailto:shinnm@mail.nih.gov)

Many human cancers and other skin ailments arise from overexpression of the polypeptide TGFbeta1 growth factor. This growth factor is a growth inhibitor whose function involves cell differentiation and development. It is thought that overexpression of this protein is a contributing factor in many diseases, including certain cancers and dermal fibrosis.

There is a need for mouse models that can exhibit overexpression of TGFbeta1 in a locally specific manner. Such is the technology being made available. The technology relates to a mouse model where the overexpression in epithelial cells is achieved via the bigenic tetracycline regulatory system. Expression of tetO TGFbeta1 occurs when the mice are bred with a second transgenic line expressing the transactivator tTa or rTa. The rTa or tTa have been coupled with keratin 5 promoters, enabling localized activation of tetO TGFbeta1 in the presence or absence of tetracyclines upon successful mating. The potential uses of these models is invaluable and can assist similar research involving different tissue specificity.

Dated: April 14, 2005.

**Steven M. Ferguson,**  
*Director, , Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 05-8546 Filed 4-28-05; 8:45 am]

BILLING CODE 4140-01-P

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Cancer Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Colorectal Cancer Screening in Primary Care Practice.

*Date:* June 14–15, 2005.

*Time:* 9:30 a.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878.

*Contact Person:* Marvin L. Salin, PhD, Scientific Review Administrator, Special Review and Logistics Branch, Division of Extramural Activities, 6116 Executive Boulevard, Room 7073, MSC8329, Bethesda, MD 20892–8329. (301) 496–0694. [msalin@mail.nih.gov](mailto:msalin@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

*Dated:* April 22, 2005.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05–8547 Filed 4–28–05; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Heart, Lung and Blood Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Sickle Cell Disease Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* Sickle Cell Disease Advisory Committee.

*Date:* June 6, 2005.

*Time:* 8:30 a.m. to 4 p.m.

*Agenda:* Discussion of program policies and issues.

*Place:* National Institute of Health, 6701 Rockledge Drive, Room 9112, Bethesda, MD 20892.

*Contact Person:* Charles M. Peterson, MD, Director, Blood Diseases Program, Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, NIH, Two Rockledge Center, Room 10158, MSC 7950, 6701 Rockledge Drive, Bethesda, MD 20892, 301/435–0080.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page <http://www.nhlbi.nih.gov/meetings/index/htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

*Dated:* April 21, 2005.

**LaVerne Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05–8550 Filed 4–28–05; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselors, NHLBI.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Heart, Lung, and Blood Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Board of Scientific Counselors, NHLBI.

*Date:* June 8–9, 2005.

*Time:* June 8, 2005, 7 p.m. to 9 p.m.

*Agenda:* To review and evaluate personal qualifications and performance, and competence of individual investigators.

*Place:* Embassy Suites Pavillion, 4300 Military Road, NW., Washington, DC 20015.

*Time:* June 9, 2005, 7:15 a.m. to 4:30 p.m.

*Agenda:* To review and evaluate the Molecular Disease Branch and the Pulmonary Critical Care Medicine Branch.

*Place:* Embassy Suites Pavillion, 4300 Military Road, NW., Washington, DC 20015.

*Contact Person:* Robert S. Balaban, PhD, Scientific Director, Division of Intramural Research, National Institutes of Health, NHLBI, Building 10, Room 7N214, MSC 1668, 10 Center Drive, Bethesda, MD 20892, (301) 496–2116.

Information is also available on the Institute's/Center's home page: <http://www.nhlbi.nih.gov/meetings/index.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233 National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

*Dated:* April 21, 2005.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05–8551 Filed 4–28–05; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the AIDS Research Advisory Committee, NIAID.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* AIDS Research Advisory Committee, NIAID.

*Date:* May 23, 2005.

*Time:* 1 p.m. to 4 p.m.

*Agenda:* Report from the Division Director, discussion of Division programs.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Conference Room E1/E2, Bethesda, MD 20892 (Telephone Conference Call).